Ionis Pharmaceuticals, Inc. (IONS) Stock Price & How to Invest
Short answer
IONS is Ionis Pharmaceuticals, the pioneer of antisense (RNA-targeted) drug technology now transitioning into a commercial-stage biotech with its own marketed medicines. Investing here is a bet that its wholly owned launches (Tryngolza, Dawnzera) plus a deep late-stage pipeline can carry it to sustained profitability.
IONS stock price
As of 2026-07-09, Ionis Pharmaceuticals, Inc. (IONS) last closed at $64.27, up 51.7% over the past year. Over the past 52 weeks it has traded between $40.69 and $86.50.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Ionis Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Ionis Pharmaceuticals, Inc. (IONS) do?
Ionis Pharmaceuticals is a California-based biotechnology company that invented and commercialized antisense technology, a way to design short strands of nucleic acid that silence or modify the RNA behind disease-causing proteins. For decades it operated largely as an R&D and royalty engine, partnering drugs like Spinraza (spinal muscular atrophy, with Biogen) and Wainua (hereditary ATTR polyneuropathy, with AstraZeneca) to larger companies. It now markets around seven medicines and, starting in 2025, launched its first fully owned products, Tryngolza (olezarsen) for familial chylomicronemia syndrome and Dawnzera for hereditary angioedema.
The investment picture is a classic biotech transition story. Revenue is scaling quickly (up roughly 87 percent year over year in Q1 2026) as owned launches ramp and milestone payments flow in, and management has been raising guidance and peak-sales expectations for olezarsen. The company still runs an operating loss and carries the binary risks of any drug developer: regulatory decisions, Phase 3 readouts, and competition. So the picture rewards investors comfortable with a well-capitalized, pipeline-rich biotech that has not yet proven durable profitability.
What's driving Ionis Pharmaceuticals, Inc. (IONS)?
1. Owned commercial launches
Ionis is shifting from a royalty-and-partnership model to selling its own drugs, led by Tryngolza and Dawnzera launched in 2025. Owning full economics on these products, rather than splitting them with partners, is the core lever for higher revenue and eventual profitability.
2. Olezarsen label expansion
Olezarsen (Tryngolza) has an FDA priority-review filing for severe hypertriglyceridemia, a far larger population than its initial rare-disease indication. Management has raised peak annual net-sales guidance for the franchise to over $3 billion, making this expansion the single biggest swing factor for the stock.
3. Deep late-stage pipeline
Ionis entered 2026 with a packed catalyst calendar, including additional potential launches such as zilganersen for Alexander disease and roughly five expected Phase 3 readouts. A broad antisense platform lets it address many rare and cardiometabolic diseases in parallel.
4. Strong balance sheet
The company ended 2025 with roughly $2.7 billion in cash and investments and held about $1.9 billion mid-2026, giving it runway to fund launches and trials without immediate financing pressure. That cushion reduces the dilution risk common to earlier-stage biotech.
What are the risks to Ionis Pharmaceuticals, Inc. (IONS)?
Ionis still operates at a loss, with 2026 non-GAAP operating loss guidance in the range of roughly $425 million to $475 million, so profitability remains unproven. Its value is heavily tied to a handful of launches and regulatory decisions, meaning a disappointing Phase 3 readout, a delayed or rejected FDA filing, or a slow launch could sharply pressure the stock. It competes directly with Alnylam's RNA-interference platform in overlapping rare and cardiovascular diseases, and some of its biggest products are shared with partners like Biogen and AstraZeneca who control much of the commercial reach. Pricing pressure, safety findings, and patent or competitive erosion on older drugs add further uncertainty. As a biotech, the shares can be highly volatile around clinical and regulatory events.
How is Ionis Pharmaceuticals, Inc. (IONS) valued? (approximate, JULY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Ionis Pharmaceuticals, Inc.'s investor relations page or your broker.
- Market cap: ~$14B
- Revenue (2025): ~$944M
- Q1 2026 revenue: ~$246M (up ~87% YoY)
- 2026 revenue guidance: ~$875M-$900M
- Cash and investments: ~$1.9B
- 2026 non-GAAP operating loss guidance: ~$425M-$475M
Ionis trades as a growth-stage biotech, valued on future product sales rather than current earnings since it remains unprofitable. Revenue is accelerating on owned launches and milestone payments, and management raised full-year 2026 guidance after a strong first quarter. The valuation embeds significant expectations for olezarsen's expansion and the broader pipeline.
Who competes with Ionis Pharmaceuticals, Inc. (IONS)?
RNA-targeted medicine peers
Alnylam Pharmaceuticals is the closest competitor, using RNA interference (a different mechanism from Ionis's antisense) to target overlapping rare and cardiovascular diseases, and it carries a substantially larger market cap. Both are leaders in the broader oligonucleotide-therapeutics field alongside players like Astellas.
Large pharma in shared indications
In big categories such as cardiometabolic and amyloid disease, Ionis faces established pharmaceutical companies with far larger sales forces, including some that are simultaneously partners (AstraZeneca on Wainua, Biogen on Spinraza and Qalsody) and potential competitors in adjacent treatments.
Rare-disease and cardiometabolic specialists
Individual products compete with focused biotech and specialty-pharma rivals in areas like hereditary angioedema, hypertriglyceridemia, and neuromuscular disease, where alternative therapies and newer entrants can pressure market share and pricing.
How to invest in Ionis Pharmaceuticals, Inc. (IONS)
There are three common ways to get IONS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so IONS sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where IONS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Ionis Pharmaceuticals, Inc. (IONS)
Ionis is an antisense-drug pioneer turning a long-running research engine into commercial products, so the story hinges on launch execution and pipeline readouts rather than current profits.
More on Ionis Pharmaceuticals, Inc. (IONS)
Whether IONS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IONS a buy?, and where the stock could go from here in the IONS stock forecast.
For income investors, whether IONS pays a dividend and how the payout looks is covered in does IONS pay a dividend?
Build a basket around IONS with Walnut
Use Ionis Pharmaceuticals, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Ionis Pharmaceuticals do?
+
Ionis is a commercial-stage biotechnology company that pioneered antisense technology, designing RNA-targeted drugs that silence or modify disease-causing proteins. It markets several medicines and develops a broad pipeline across rare, neurological, and cardiometabolic diseases.
Is Ionis profitable?
+
Not yet on a sustained basis. Revenue is growing quickly, but the company still guides to a non-GAAP operating loss for 2026 (roughly $425 million to $475 million) as it invests in launches and trials. Profitability depends on its owned products scaling up.
What are Ionis's most important drugs?
+
Its first wholly owned launches are Tryngolza (olezarsen) for familial chylomicronemia syndrome and Dawnzera for hereditary angioedema. It also has partnered products including Spinraza, Wainua, Qalsody, Tegsedi, and Waylivra.
Why is olezarsen important to Ionis?
+
Olezarsen (Tryngolza) has an FDA priority-review filing to expand into severe hypertriglyceridemia, a much larger patient population. Management has raised peak annual net-sales guidance for the franchise to over $3 billion, making it a central driver of the company's outlook.
How is antisense different from RNA interference?
+
Both target RNA rather than proteins directly, but they use different molecular mechanisms. Ionis is the leader in antisense oligonucleotides, while its main peer Alnylam specializes in RNA interference. The two approaches sometimes address overlapping diseases.
Who are Ionis's main competitors?
+
Alnylam Pharmaceuticals is the closest comparable in RNA-targeted medicine. Ionis also competes with large pharmaceutical companies in shared indications and with specialty biotech firms in specific rare and cardiometabolic diseases.
How financially stable is Ionis?
+
The company is well capitalized, ending 2025 with about $2.7 billion in cash and investments and holding roughly $1.9 billion in mid-2026. That gives it runway to fund launches and clinical programs, though it is still spending more than it earns.
What makes Ionis stock volatile?
+
As a biotech, its value is tied to regulatory decisions, launch trajectories, and clinical readouts. With around five Phase 3 readouts and multiple FDA decisions on its 2026 calendar, individual events can move the shares sharply in either direction.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Ionis Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.